Foscarbidopa
AbbVie’s Parkinson’s Disease Therapy Rejected by FDA Due to Third-Party Manufacturer Issues
AbbVie, Parkinson’s disease, FDA, ABBV-951, foscarbidopa, foslevodopa, third-party manufacturer, regulatory issues
Actionable Insights Powered by AI
AbbVie, Parkinson’s disease, FDA, ABBV-951, foscarbidopa, foslevodopa, third-party manufacturer, regulatory issues